#1 Clinical Trials Search in Europe

Regtivex

This article explores the use of Regtivex, an innovative drug being studied in clinical trials for kidney transplant recipients. Regtivex is part of a new approach that combines regulatory T cell therapy with other treatments to potentially improve transplant outcomes and reduce the need for long-term immunosuppression.

Table of Contents

What is REGTIVEX?

REGTIVEX, also known as “Expanded Tregs_04” or “Expanded regulatory T cells_04”, is an innovative medical treatment being studied for patients undergoing kidney transplantation[1]. It is classified as a cell therapy, which means it uses living cells as a therapeutic agent[1]. Specifically, REGTIVEX is made up of regulatory T cells, a type of immune cell that helps control the body’s immune responses[1].

How REGTIVEX Works

REGTIVEX is designed to help kidney transplant recipients by modulating their immune system. The therapy involves:

  1. Expanding the patient’s own regulatory T cells in a laboratory
  2. Infusing these expanded cells back into the patient
  3. Combining this treatment with other medications to create a more tolerant environment for the transplanted kidney

The goal is to reduce the risk of the body rejecting the new kidney while potentially allowing for a reduction in other immunosuppressive medications[1].

Clinical Trial Overview

REGTIVEX is currently being studied in a clinical trial called “Trex”[1]. This trial is designed to evaluate the safety and effectiveness of REGTIVEX when used alongside other treatments in patients receiving kidney transplants from living donors who are not perfectly matched in terms of their HLA (Human Leukocyte Antigen) type[1].

The main objectives of the trial are:

  • To examine the safety of REGTIVEX therapy when used with tocilizumab (another medication) and donor bone marrow in kidney transplant recipients
  • To assess chimerism levels (the presence of donor cells in the recipient’s body) within the first month after transplant[1]

Potential Benefits

The researchers hope that REGTIVEX therapy may offer several benefits to kidney transplant recipients:

  • Potentially reducing the need for long-term immunosuppressive medications
  • Promoting a more tolerant immune environment for the transplanted kidney
  • Possibly decreasing the frequency of rejection episodes
  • Potentially improving long-term kidney graft function

These potential benefits are being carefully studied in the clinical trial to determine if REGTIVEX can indeed provide these advantages[1].

Eligibility Criteria

The clinical trial has specific criteria for who can participate. Some key eligibility factors include:

  • Being 18 years or older
  • Planning to receive a kidney transplant from a living donor
  • The donor and recipient not being perfectly HLA-matched
  • Not having certain viral infections (like HIV or chronic hepatitis)
  • Not having had a previous organ transplant

It’s important to note that there are additional criteria, and a healthcare provider would need to assess each individual case[1].

Safety Considerations

As with any new medical treatment, safety is a top priority in the REGTIVEX clinical trial. The researchers are closely monitoring for any potential side effects or complications, including:

  • Graft-versus-host disease (GVHD): A condition where donor cells attack the recipient’s body
  • Impaired graft function: Monitoring if the transplanted kidney is working properly
  • Overall patient health and survival

These safety aspects are being carefully evaluated throughout the 12-month period following the transplant[1].

Aspect Details
Drug Name Regtivex (Expanded Tregs_04)
Trial Phase Phase I and II integrated trial
Target Condition Kidney transplantation
Main Objectives 1. Examine safety of Regtivex with tocilizumab and donor bone marrow
2. Assess chimerism levels within first month post-transplant
Key Secondary Objectives 1. Evaluate potential for immunosuppression reduction
2. Assess changes in immune system indicating tolerance
3. Monitor frequency of rejection episodes
4. Assess kidney graft function
Administration Method Intravenous infusion
Key Eligibility Criteria 1. Adults (18+ years)
2. Planned living donor kidney transplant recipients
3. ABO-compatible, non-HLA-identical donors
4. Negative for donor-specific antibodies
Primary Endpoints 1. Safety: Incidence of GVHD, impaired graft function, or patient death
2. Efficacy: Peak chimerism levels within first month

FAQ

  • What is Regtivex? Regtivex is a drug containing expanded regulatory T cells, which are a type of immune cell that helps control the body's immune response. It's being studied as part of a new treatment approach for kidney transplant recipients.
  • How is Regtivex administered? Regtivex is given as an intravenous infusion, which means it's delivered directly into the bloodstream through a vein.
  • What are the main goals of the Regtivex clinical trial? The main goals are to examine the safety of Regtivex therapy when combined with other treatments in kidney transplant recipients, and to assess the levels of donor cells in the recipient's body (chimerism) within the first month after transplant.
  • Who can participate in the Regtivex clinical trial? The trial is open to adults (18 years or older) who are planned recipients of a living donor kidney transplant. Participants must meet specific criteria, including having a donor that is not HLA-identical and being negative for donor-specific antibodies.
  • What potential benefits are researchers hoping to see with Regtivex? Researchers hope that Regtivex, combined with other treatments, might allow for a reduction in immunosuppression medications over time, potentially leading to better long-term outcomes for kidney transplant recipients. They're also looking for signs that the treatment promotes tolerance of the transplanted kidney by the recipient's immune system.

Ongoing Clinical Trials on Regtivex

  • Study on the Safety and Effectiveness of Regtivex and Tocilizumab in Patients Receiving HLA-Mismatched Living Donor Kidney Transplants

    Not recruiting

    1 1 1 1
    Investigated Diseases:
    Investigated Drugs:
    Austria

Glossary

  • Regulatory T cells: A type of immune cell that helps control the body's immune response and prevent it from attacking healthy tissues or transplanted organs.
  • HLA-mismatched: When the human leukocyte antigens (HLA) of the donor and recipient are not identical, which is common in transplantation and can increase the risk of rejection.
  • Chimerism: The presence of donor cells in the recipient's body after transplantation, which can be a sign of successful engraftment.
  • Tocilizumab: A medication that suppresses the immune system and is being studied alongside Regtivex in this trial.
  • Immunosuppression: The intentional reduction of the body's immune response, typically used to prevent rejection of transplanted organs.
  • Graft-versus-host disease (GVHD): A potential complication where transplanted donor cells attack the recipient's body.
  • eGFR: Estimated glomerular filtration rate, a measure of kidney function.
  • Biopsy-proven acute rejection: When a tissue sample from the transplanted kidney shows signs of the recipient's immune system attacking the organ.
  • Subclinical rejection: Rejection of the transplanted organ that is detected through routine testing but doesn't cause noticeable symptoms.
  • Donor-specific antibodies (DSA): Antibodies in the recipient's blood that react specifically against the donor's tissues, which can increase the risk of rejection.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-regtivex-and-tocilizumab-in-patients-receiving-hla-mismatched-living-donor-kidney-transplants/